April

/
/
April
Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters

CAMBRIDGE, England, April 26, 2017 /PRNewswire/ —¬†Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment…

Start typing and press Enter to search

Shopping Cart